Rani Therapeutics Holdings, Inc.
NASDAQ:RANIBiotechnology
Healthcare
$0.80 -5.22%
-$0.04 today
- Market cap
- $52.19M
- Beta
- 0.76
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.16
52W Low $0.39High $3.87
Volume 0.23M
Average 1.15M
Income Statement
Follow revenue through to earnings.
Revenue
$1.63M
FY 2025 · Annual
+58.9% YoYOperating Income
-$38.31M
FY 2025 · Annual
Net Income
-$29.67M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.72M | 0 | 0 | 1.03M | 1.63M |
| Cost of Revenue | 0 | 0 | 822K | 0 | 900K |
| Gross Profit | 2.72M | 0 | (822K) | 1.03M | 733K |
| Gross Margin | 100.0% | — | — | 100.0% | 44.9% |
| Research & Development | 26.48M | 36.61M | 39.62M | 26.68M | 20.21M |
| Selling, General & Admin | 27.83M | 26.84M | 26.48M | 23.95M | 19.74M |
| Operating Expenses | 54.32M | 63.45M | 65.28M | 54.34M | 39.04M |
| Depreciation & Amortization | 497K | 548K | 822K | 1.03M | 900K |
| EBITDA | (52.08M) | (61.66M) | (61.98M) | (50.52M) | (37.16M) |
| EBITDA Margin | -1917.0% | — | — | -4914.7% | -2275.5% |
| Operating Income | (51.6M) | (63.45M) | (66.1M) | (53.31M) | (38.31M) |
| Operating Margin | -1899.1% | — | — | -5186.2% | -2346.0% |
| Interest Income | 89K | 1.25M | 3.3M | 1.76M | 827K |
| Interest Expense | 466K | 1.07M | 5.09M | 5.03M | 2.89M |
| Other Income / Expenses | (1.45M) | 177K | (1.78M) | 23.3M | (2.64M) |
| Income Before Tax | (53.05M) | (63.27M) | (67.88M) | (30.02M) | (40.95M) |
| Pre-Tax Margin | -1952.4% | — | — | -2920.0% | -2507.7% |
| Income Tax Expense | 41K | 70K | 0 | 26.57M | 0 |
| Net Income | (8.33M) | (30.59M) | (33.97M) | (30.02M) | (29.67M) |
| Net Margin | -306.6% | — | — | -2920.0% | -1817.1% |
| EPS (Basic) | (0.42) | (1.28) | (1.33) | (1.05) | (0.45) |
| EPS (Diluted) | (0.42) | (1.28) | (1.33) | (1.05) | (0.45) |
| 19.53M | 23.82M | 25.51M | 28.48M | 66.14M | |
| 19.53M | 23.82M | 25.51M | 28.48M | 66.14M |
RANI Earnings Waterfall · TTM
NASDAQ:RANI · Revenue to Net Income
Key Ratios
EPS$-0.41
Gross Margin47.6%
Net Margin-279.3%
P/E Ratio-2.8
P/S Ratio53.3
Analysis
$3.2M of revenue converted into -$29.4M of net income for the selected period. Gross margin is 47.6% and net margin is -279.3%, showing how much revenue survives after costs and taxes. EPS is $-0.41, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Sep 29, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 29, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| 10-Q | Quarterly report | Aug 13, 2026 | |
| 8-K | Current report | Aug 13, 2026 |
How much revenue does RANI generate?
Rani Therapeutics Holdings, Inc. (RANI) reported $1.63M of revenue in fiscal 2025.
Is RANI profitable?
Rani Therapeutics Holdings, Inc. (RANI) reported -$29.67M of net income, with a net margin of -1817.1%.
Continue the stock analysis
Jump to another research area for this company.